Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for prevention of type 1 diabetes in stage 2 autoimmune diabetes
RBR-723bk5pPhase 2Not yet recruiting
- Sponsor
- Federal University of Ceará
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of linagliptin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Federal University of Ceará. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
linagliptin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on RBR-723bk5p.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-723bk5p.